Performance, transparency, trust

We’re proud of the value we create for all our stakeholders, and strive to communicate our performance in a clear and timely manner. Download the latest reports, or stay up to date on various metrics of our market performance here. If you have any queries not addressed here, please feel free to get in touch with Investor Relations on our Contact page. 


Observe Medical ASA was listed on Oslo Børs 4 November 2019. Our ambition is to provide shareholders, analysts and investors simultaneous access to accurate, clear and relevant information. We aim to make all our communication to the financial market available on this web site. 

Read our latest regulatory news

Observe Medical ASA – Grant of options

16 November 2021: The board of directors of Observe Medical ASA (the "Company") has resolved to grant 120,000 share options in the Company to the group CFO, Per Arne Nygård. Per Arne Nygård was engaged as interim CFO of the group as an consultant on 10 December 2019, and was permanently employed as CFO of…

Read more

Observe Medical ASA: Interim report for the third quarter and 2021

Oslo, November, 3rd, 2021 – Observe Medical ASA (OSE: OBSRV) today released its financial results and presentation of the third quarter of 2021. The Company reports strong revenue growth for the Nordic portfolio, continued progress in the commercialization and go-to-market execution for Sippi® including an update on preparations for US market entry. CEO of Observe Medical,…

Read more

Observe Medical ASA: Invitation to third quarter 2021 presentation

Observe Medical ASA invites you to a presentation of the third quarter 2021. The presentation will take place at Felix Konferansesenter in Oslo on Wednesday, November 3rd. The event will start at 08.30 CET and will be webcasted live on – Investor relations and at the following link: Representatives from the Company will…

Read more

Financial calendar

  • 3 November 2021

    Quarterly Presentation - Q3 2021

  • 17 February 2022

    Quarterly Presentation - Q4 2021

  • 29 April 2022

    Annual Report (publish)

  • 12 May 2022

    Quarterly Presentation - Q1 2022

  • 2 June 2022

    Annual General Meeting

  • 25 August 2022

    Quarterly Presentation - Q2 and First Half Report 2022

  • 3 November 2022

    Quarterly Presentation - Q3 2022

The Share

Share performance


Last updated 25 October 2021

NameNumber of shares% of top 20% of totalCountry
1NAVAMEDIC ASA 4,222,727  25.08%21.54%Norway
2INGERØ REITEN INV. COMPANY AS 3,939,394  23.40%20.09%Norway
3RO, LARS 1,501,051  8.92% 7.66%NORWAY
5ARTAL AS 1,064,457 6.32% 5.43%Norway
6ALPINE CAPITAL AS 745,446 4.43% 3.80%Norway
7Soleglad Invest AS 586,668 3.49% 2.99% NORWAY
8NORDA ASA 511,632 3.04% 2.61%NORWAY
9TRANBERGKOLLEN INVEST AS 500,000  2.97% 2.55%Norway
10LEIKERANE AS 373,439  2.22% 1.90%Norway
11LAPAS AS 348,326 2.07% 1.78%Norway
12GINNY INVEST AS 270,030 1.60% 1.38%NORWAY
13PHILIP HOLDING AS 260,000 1.54% 1.33%NORWAY
15cam as 181,000 1.08% 0.92%NORWAY
16mp pENSJON PK 176,135 1.05% 0.90%NORWAY
17Bjørntvedt, vegard 148,220 0.88% 0.76%norway
18Nordnet bank ab 137,101 0.81% 0.70%sweden
19ABC INVEST AS 120,000 0.71% 0.61%NORWAY
20pettersen, gunerius 115,013 0.68% 0.59%Norway
Total numBer owned by top 2016,834,011100.00%85.86%
Total number of shares19,605,457

Basic share data

Stock Exchange:


First day of listing:


Trading Currency:


Number of shares issued:

Nominal value:

Euronext Expand Oslo


4 November 2019




19 605 457

NOK 0.26


Nomination committee

The Articles of Association provide for a nomination committee composed of two or three members. The current members of the nomination committee are Bård Brath Ingerø (chair) and Grete Hogstad.

The nomination committee is responsible for nominating candidates for the election of shareholder-elected members and chairperson to the Board of Directors and for nominating members to the nomination committee, as well as making recommendations for remuneration of these.

For nomination committee please contact:
Bård Brath Ingerø, Chair of the Nomination Committee
+47 92 83 33 34 /

IR contact

Björn Larsson, Chief Executive Officer
+46 766 201 725 /

Per Arne Nygård, Chief Financial Officer
+47 41 10 43 45 /

Sign up for the mailing list